Increased Levels of Serum Fibroblast Growth Factor-2 in Diabetic Pregnant Women with Retinopathy1
D. J. Hill,
A. Flyvbjerg,
E. Arany,
F. F. Lauszus and
J. G. Klebe
Medical Research Council Group in Fetal and Neonatal Health and
Development, Lawson Research Institute, St. Josephs Health Center
(D.J.H., E.A.), London, Ontario, Canada N6A 4V2; the Departments of
Medicine (D.J.H., E.A.), Pediatrics (D.J.H.), and Physiology (D.J.H.),
University of Western Ontario, London, Ontario, Canada N6A 5O5; the
Institute of Experimental Clinical Research, Aarhus Kommunehospital
(A.F.), DK-8000 Aarhus C., Denmark; and the Gynecological and
Obstetrical Department, Skejby University Hospital (F.F.L., J.G.K.),
DK-8200 Aarhus N., Denmark
Address all correspondence and requests for reprints to: Dr. D. J. Hill, Lawson Research Institute, St. Josephs Health Center, 268 Grosvenor Street, London, Ontario, Canada N6A 4V2. E-mail:
dhill{at}lri.stjosephs.london.on.ca
Fibroblast growth factor-2 (FGF-2) is a potent mitogen and angiogenic
factornormally absent from the adult circulation. We have previously
shownthat it appears in normal maternal serum and that circulating
FGF-2levels are elevated in pregnancies complicated by diabetes.This
study was performed to determine whether serum FGF-2 ismore abundant
in pregnant diabetic women with retinopathy thanin those without.
Serum was collected monthly between 1430weeks gestation and every 2
weeks from then until delivery (3538weeks) from 36 women with type 1
diabetes. FGF-2 was extractedby heparin-Sepharose affinity
chromatography and quantifiedby specific RIA. Patients were divided
according to the Whiteclassification of diabetes. In 17 women without
retinopathy(White groups B, C, and D0), immunoreactive
FGF-2 was detectableat 14 weeks (mean ± SEM,
154 ± 39 pmol/L), wasmaximal after 26 weeks (306 ± 38
pmol/L), after whichvalues steadily declined to term (212 ± 48
pmol/L). In19 women with simplex or proliferative retinopathy (White
groupsD+ and R), circulating levels of FGF-2 were
significantly greaterbetween 2232 weeks gestation (22 weeks,
480 ±102 vs. 239 ± 38 pmol/L;
P < 0.05). Serum FGF-2 wassignificantly
correlated with hemoglobin A1c levels at 22, 30,
and34 weeks gestation. The mean birth weight of the infants didnot
significantly differ between groups. Macroalbuminuria wasabsent in all
patients, and creatinine clearance and blood pressuredid not
significantly differ between the two groups. The resultssuggest that
serum FGF-2 is substantially elevated in pregnantdiabetic women with
retinopathy in second and early third trimesters.It is unlikely that
in these patients this was primarily dueto altered FGF-2 clearance,
but may relate to excessive productionby the utero-placental
compartment. The high circulating levelsof FGF-2 may be causally
related to the development of diabeticretinopathy.
This article has been cited by other articles:
R. Vasko, M. Koziolek, M. Ikehata, M. P. Rastaldi, K. Jung, H. Schmid, M. Kretzler, G. A. Muller, and F. Strutz Role of basic fibroblast growth factor (FGF-2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts
Am J Physiol Renal Physiol,
June 1, 2009;
296(6):
F1452 - F1463.
[Abstract][Full Text][PDF]
F. F. Lauszus, J. G. Klebe, T. Bek, and A. Flyvbjerg Increased Serum IGF-I During Pregnancy Is Associated With Progression of Diabetic Retinopathy
Diabetes,
March 1, 2003;
52(3):
852 - 856.
[Abstract][Full Text][PDF]
C. Kurz, L. Hefler, H. Zeisler, C. Schatten, P. Husslein, and C. Tempfer Maternal Basic Fibroblast Growth Factor Serum Levels Are Associated With Pregnancy-Induced Hypertension
Reproductive Sciences,
January 1, 2001;
8(1):
24 - 26.
[Abstract][PDF]
A. Eliakim, Y. Oh, and D. M. Cooper Effect of single wrist exercise on fibroblast growth factor-2, insulin-like growth factor, and growth hormone
Am J Physiol Regulatory Integrative Comp Physiol,
August 1, 2000;
279(2):
R548 - R553.
[Abstract][Full Text][PDF]